阿尔茨海默病中的奥雷辛-A和循环节障碍:对粉样β病理学的影响
Ravinder Singh1, Vajinder Kaur1, Anushka Ash2
1Department of Biotechnology, Guru Nanak Dev University, Amritsar, 143005, Punjab, India.
Molecular neurobiology
|December 3, 2025
概括
奥雷辛-A抑制了粉样β聚合,这是阿尔茨海默病 (AD) 的关键因素. 这种神经可能为阿兹海默症患者的认知衰退和昼夜功能障碍提供治疗标.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 时间生物学 时间生物学
背景情况:
- 阿尔茨海默病 (AD) 标志着认知能力下降,昼夜节律受损,以及粉样β (Aβ) 斑块的积累.
- 调节睡眠和昼夜节律的神经Orexin-A与阿尔茨海默病有关,但它对Aβ聚合的影响尚不清楚.
研究的目的:
- 研究素A对Aβ聚合的影响.
- 在急性睡眠剥夺 (ASD) 后,评估OREXIN-A对AD小鼠认知和昼夜功能障碍的影响.
主要方法:
- 对认知功能 (识别,空间记忆) 的行为评估.
- 蛋白质组分析以确定与AD,认知,昼夜节律和Aβ清除相关的调节蛋白质.
- 分子动力学 (MD) 模拟以研究素-A和Aβ相互作用.
主要成果:
- 在AD小鼠中,ASD诱导了显著的认知缺陷和调节失调的时钟和Bmal1水平.
- 蛋白质组分析发现了许多调节的蛋白质,包括与AD和昼夜节律相关的蛋白质.
- MD模拟显示了素-A与Aβ的高亲和结合,抑制其聚合.
结论:
- 奥雷辛-A在抑制Aβ聚合和减轻Aβ诱导的神经毒性方面表现出潜力.
- 在阿尔茨海默病中,奥雷辛-A可能在调节Aβ聚合和昼夜功能障碍方面发挥关键作用.
- 奥雷辛-A代表了一个潜在的治疗目标,可以减缓AD的认知衰退和神经退行.
更多相关视频
06:23A Chronic Sleep Fragmentation Model using Vibrating Orbital Rotor to Induce Cognitive Deficit and Anxiety-Like Behavior in Young Wild-Type Mice
Published on: September 22, 2020
6.0K
08:58Optogenetic Manipulation of Neural Circuits During Monitoring Sleep/wakefulness States in Mice
Published on: June 19, 2019
10.4K
相关概念视频
Circadian Rhythms and Gene Regulation
4.5K
The biological clock is involved in many aspects of regulating complex physiology in all animals. It was in 1935 when German zoologists, Hans Kalmus and Erwin Bünning, discovered the existence of circadian rhythm in Drosophila melanogaster. However, the internal molecular mechanisms behind the circadian clock remained a mystery until 1984, when Jeffrey C. Hall, Michael Rosbash, and Michael W. Young discovered the expression of the Per gene oscillating over a 24-hour cycle. In subsequent...
4.5K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764
